Recent studies have demonstrated tolerability and improved induction remission in younger adults with de novo FLT3-ITD AML treated with sorafenib and chemotherapy, although OS did not differ between the chemotherapy and chemotherapy/sorafenib arms (77). This evidence concerns the gene FLT3 and acute myeloid leukemia.